October 30, 2025 — Leads & Copy —
Edwards Lifesciences (NYSE: EW) reported its Q3 financial results, with sales up 14.7% to $1.55 billion and adjusted EPS at $0.67. TAVR sales increased by 12.4%, while TMTT sales reached $145.2 million, driven by PASCAL and EVOQUE adoption. The company is raising its full-year sales and EPS guidance.
According to CEO Bernard Zovighian, the company’s strong performance, driven by its broad portfolio and global presence, has led to increased 2025 sales and EPS guidance. Edwards is committed to providing complete therapies for heart patients. TAVR sales were $1.15 billion, up 12.4%, spurred by clinicians prioritizing aortic stenosis treatment. Updated ESC/EACTS guidelines have simplified care pathways for severe AS patients, even those without symptoms.
The company’s TMTT portfolio saw impressive growth, contributing significantly to overall performance. Adoption of PASCAL and EVOQUE systems remains strong, and positive clinical results have followed the introduction of SAPIEN M3 in Europe. Surgical sales grew 7.5%, driven by adoption of RESILIA therapies. The TCT conference featured data on Edwards’ transcatheter therapies, with 7-year data confirming the long-term benefits of SAPIEN TAVR valves. Cash and equivalents totaled $3 billion.
Edwards is increasing its full-year total company sales growth guidance to the high end of 9% to 10% and its underlying growth rate guidance for TAVR to 7% to 8%. Adjusted EPS is now expected to be between $2.56 and $2.62.
Contact:
Source: Edwards Lifesciences
